Stock Events

Stock Events

Search...

Genprex

0

00

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

27NovExpected

Q1 2024

Q2 2024

Next

-3.39

-3.1

-2.81

-2.52

Expected EPS

-2.523885

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2DE0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Ayala Pharmaceuticals

Advaxis, Inc. is involved in the discovery, development, and commercialization of cancer immunotherapies, offering a direct alternative to Genprex's oncology treatments.

Gilead Sciences

Gilead Sciences, Inc. has a broad portfolio of cancer therapies, including gene therapies, making it a major competitor in the oncology market.

bluebird bio, Inc. specializes in gene therapies for genetic diseases and cancer, directly competing with Genprex's gene therapy approach.

Sangamo Therapeutics

Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the same innovative treatment space as Genprex.

CRISPR Therapeutics

CRISPR Therapeutics AG is a leader in gene editing technology, which can be applied to cancer treatment, making it a competitor in the gene therapy market.

Intellia Therapeutics

Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a cutting-edge technology for treating genetic diseases and cancer, competing with Genprex's gene therapy approach.

Editas Medicine

Editas Medicine, Inc. works on gene editing technologies, including CRISPR, for the treatment of serious diseases, offering an alternative to Genprex's therapies.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics for the treatment of genetic diseases, indirectly competing with Genprex's gene therapy approach by offering a different method of genetic intervention.

About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Show more...

CEO

Mr. John Rodney Varner

Employees

22

Country

United States

ISIN

US3724462037

WKN

000A3E3Z3

Listings